Lazuriton Nano Biotechnology 10-K 3 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 02, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Lazuriton Nano Biotechnology (U.S.A.) Inc.
Entity Central Index Key	1,666,178
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		100,000,000
Entity Public Float			$ 0
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

BALANCE SHEET

BALANCE SHEET - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 1,193	$ 100,928
Total Current Assets	1,193	100,928
Total Assets	1,193	100,928
Current Liabilities
Accrued expenses	11,231	5,680
Due to related parties	94,201	223,631
Total Current Liabilities	105,432	229,311
Total Liabilities	105,432	229,311
Stockholders' Deficit
Common stock, $0.0001 par value; 750,000,000 shares authorized,100,000,000 and 60,000,000 shares issued and outstanding as of December 31, 2017 and 2016, respectively	10,000	6,000
Additional paid-in capital	250,000	54,000
Accumulated deficits	(364,239)	(188,383)
Total stockholders' deficit	(104,239)	(128,383)
Total Liabilities and Stockholders' Deficit	$ 1,193	$ 100,928

BALANCE SHEET (Parentheticals)

BALANCE SHEET (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued shares	100,000,000	60,000,000
Common stock, shares outstanding	100,000,000	60,000,000

STATEMENT OF OPERATIONS

STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Net revenue	$ 0	$ 0
General and administrative expenses	175,864	58,382
Loss from operations	(175,864)	(58,382)
Other income
Interest income	8	15
Total other income	8	15
Loss before income taxes	(175,856)	(58,367)
Provision for income taxes	0	0
Net loss	$ (175,856)	$ (58,367)
Net loss per share
Basic and diluted (in dollars per share)	$ 0	$ 0
Weighted Average Shares Outstanding:
Basic and diluted (in shares)	93,534,247	60,000,000

STATEMENT OF CASH FLOWS

STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash Flows from Operating Activities
Net loss	$ (175,856)	$ (58,367)
Changes in assets and liabilities:
Increase in accrued expenses	5,551	5,680
Increase(Decrease) in due to related parties	(129,430)	143,424
Net cash provided by (used in) operating activities	(299,735)	90,737
Cash Flows from Financing Activities
Issuance of common stock	200,000
Net cash provided by financing activities	200,000
Net (Decrease) Increase in cash and cash equivalents	(99,735)	90,737
Cash and Cash Equivalents
Beginning	100,928	10,191
Ending	1,193	100,928
Cash paid during the year for:
Interest	0	0
Income taxes	$ 0	$ 0

STATEMENTS OF SHAREHOLDERS' DEF

STATEMENTS OF SHAREHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2015	$ 6,000	$ 54,000	$ (130,016)	$ (70,016)
Balance (in shares) at Dec. 31, 2015	60,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss for the period			(58,367)	(58,367)
Balance at Dec. 31, 2016	$ 6,000	54,000	(188,383)	$ (128,383)
Balance (in shares) at Dec. 31, 2016	60,000,000			60,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for cash	$ 4,000	196,000		$ 200,000
Common stock issued for cash (in shares)	40,000,000
Net loss for the period			(175,856)	(175,856)
Balance at Dec. 31, 2017	$ 10,000	$ 250,000	$ (364,239)	$ (104,239)
Balance (in shares) at Dec. 31, 2017	100,000,000			100,000,000

ORGANIZATION AND BUSINESS

ORGANIZATION AND BUSINESS	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS	NOTE 1. ORGANIZATION AND BUSINESS Lazuriton Nano Biotechnology (U.S.A.) Inc., a company in the developmental stage (the “Company”), was incorporated on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company‘s business plan is to market and distribute Nano fertilizers products. The Company’s year-end is December 31.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2017
Going Concern [Abstract]
GOING CONCERN	NOTE 2. GOING CONCERN These financial statements were prepared on the basis of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $175,856 and $58,367 for the years ended December 31, 2017 and 2016, respectively, and had accumulated deficit of $364,239 and $188,383 as of December 31, 2017 and 2016, respectively, and it had no revenue from operations. The Company faces all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty. The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, its president and a member of our board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time. These financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying financial statements.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements and related notes have been prepared in conformity with accounting principles generally accepted in the United States of America. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results. Classification Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit. Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less. Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income by weighted average number of shares of common stock outstanding during each period. Diluted income per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents, and potentially dilutive securities outstanding during each period. As of December 31, 2017 and 2016, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. Subsequently, the FASB issued ASU No. 2017-13, in September 2017 and ASU No. 2018-01, in January 2018, which amends and clarifies ASU 2016-02. The ASU will be effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of determining the method of adoption and assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures. On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 4. ACCRUED EXPENSES Accrued expenses consist of the following: December 31, December 31, 2017 2016 Accrued professional fees $ 8,922 $ 3,700 Accrued transfer agent fees 1,383 0 Accrued edgar agent service fees 926 1,980 Total $ 11,231 $ 5,680

DUE TO RELATED PARTIES

DUE TO RELATED PARTIES	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
DUE TO RELATED PARTIES	NOTE 5. DUE TO RELATED PARTIES The Company has advanced funds from its officer and shareholder for working capital purposes. As of December 31, 2017 and 2016, there were $94,201 and $223,631 advances outstanding. The Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6. INCOME TAXES As of December 31, 2017, the Company had net operating loss carryforwards of approximately $362,856 that may be available to reduce future years’ taxable income through 2037. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. On December 22, 2017 1, 35% 21% January 1, 2018. 21% 2018 The provision for Federal income tax consists of the following: For the Years Ended December 31, 2017 2016 Federal income tax benefit attributable to: Current Operations $ 36,930 $ 19,845 Less: valuation allowance (36,930 ) (19,845 ) Net provision for Federal income taxes $ - $ - The tax effects of temporary differences and carry forwards that give rise to significant portions of deferred tax assets and liabilities consist of the following: December 31, 2017 December 31, 2016 Deferred tax asset attributable to: Net operating loss carryover $ 76,490 $ 64,050 Less: valuation allowance (76,490 ) (64,050 ) Net deferred tax asset $ - $ - The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below: 2017 2016 Statutory tax benefit (34 )% (34 )% Provisional remeasurement of deferred taxes 13 % - % Permanent items - % - % Change in deferred tax asset valuation allowance 21 % 34 % Provision for income taxes - % - % For the years ended December 31, 2017 and 2016, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

STOCKHOLDER'S DEFICIT

STOCKHOLDER'S DEFICIT	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDER'S DEFICIT	NOTE 7. STOCKHOLDERS’ DEFICIT On June 4, 2015, the Company sold and issued to the President and a member of board of directors 10,000 shares of common stock, $0.0001 par value for $10 in cash. On November 10, 2015, the Company sold and issued 59,990,000 shares of common stock, $0.0001 par value to forty-five shareholders for a total amount of $59,990 in cash. On March1, 2017, the Company sold and issued 40,000,000 shares of common stock, $0.0001 par value to twenty-six shareholders for a total amount of $200,000 in cash.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8. SUBSEQUENT EVENTS Management has evaluated subsequent events through the date which the financial statements are available to be issued. All subsequent events requiring recognition as of December 31, 2017 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

SUMMARY OF SIGNIFICANT ACCOUN15

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements and related notes have been prepared in conformity with accounting principles generally accepted in the United States of America.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results.
Reclassification	Classification Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Net Income (loss) per Share	Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income by weighted average number of shares of common stock outstanding during each period. Diluted income per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents, and potentially dilutive securities outstanding during each period. As of December 31, 2017 and 2016, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. Subsequently, the FASB issued ASU No. 2017-13, in September 2017 and ASU No. 2018-01, in January 2018, which amends and clarifies ASU 2016-02. The ASU will be effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of determining the method of adoption and assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures. On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	December 31, December 31, 2017 2016 Accrued professional fees $ 8,922 $ 3,700 Accrued transfer agent fees 1,383 0 Accrued edgar agent service fees 926 1,980 Total $ 11,231 $ 5,680

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of provision for Federal income tax	For the Years Ended December 31, 2017 2016 Federal income tax benefit attributable to: Current Operations $ 36,930 $ 19,845 Less: valuation allowance (36,930 ) (19,845 ) Net provision for Federal income taxes $ - $ -
Schedule of tax effects of temporary differences and carryforwards	December 31, 2017 December 31, 2016 Deferred tax asset attributable to: Net operating loss carryover $ 76,490 $ 64,050 Less: valuation allowance (76,490 ) (64,050 ) Net deferred tax asset $ - $ -
Schedule of provision for income taxes on loss before taxes	2017 2016 Statutory tax benefit (34 )% (34 )% Provisional remeasurement of deferred taxes 13 % - % Permanent items - % - % Change in deferred tax asset valuation allowance 21 % 34 % Provision for income taxes - % - %

GOING CONCERN (Detail Textuals)

GOING CONCERN (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (175,856)	$ (58,367)
Accumulated deficits	$ (364,239)	$ (188,383)

ACCRUED EXPENSES - Summary of A

ACCRUED EXPENSES - Summary of Accrued expenses (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Accrued professional fees	$ 8,922	$ 3,700
Accrued Transfer Agent Fees	1,383	0
Accrued edgar agent service fees	926	1,980
Total	$ 11,231	$ 5,680

DUE TO RELATED PARTIES (Detail

DUE TO RELATED PARTIES (Detail Textuals) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Related Party Transactions [Abstract]
Due to related parties	$ 94,201	$ 223,631
Percentage of interest rates on advances outstanding	0.00%

INCOME TAXES - Summary of provi

INCOME TAXES - Summary of provision for Federal income tax (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Federal income tax benefit attributable to:
Current Operations	$ 36,930	$ 19,845
Less: valuation allowance	(36,930)	(19,845)
Net provision for Federal income taxes	$ 0	$ 0

INCOME TAXES - Summary of tax e

INCOME TAXES - Summary of tax effects of temporary differences and carryforwards (Details 1) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax asset attributable to:
Net operating loss carryover	$ 76,490	$ 64,050
Less: valuation allowance	(76,490)	(64,050)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES - Summary of diffe

INCOME TAXES - Summary of difference between effective rate reflected in provision for income taxes (Details 2)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory tax benefit	(34.00%)	(34.00%)
Provisional remeasurement of deferred taxes	13.00%	0.00%
Permanent items	0.00%	0.00%
Change in deferred tax asset valuation allowance	21.00%	34.00%
Provision for income taxes	0.00%	0.00%

INCOME TAXES (Detail Textuals)

INCOME TAXES (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Net operating loss carry forwards	$ 362,856
Federal corporate income tax rate	(34.00%)	(34.00%)
Corporate income tax rate effective in 2018	21.00%
Discrete tax expenses (benefit)	$ 0
Lower effective tax rate	13.00%	0.00%
Maximum
Income Tax [Line Items]
Federal corporate income tax rate	35.00%

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Textuals)	Mar. 01, 2017USD ($)Shareholder$ / sharesshares	Nov. 10, 2015USD ($)Shareholder$ / sharesshares	Jun. 04, 2015USD ($)$ / sharesshares
Stockholders' Equity Note [Abstract]
Number of common stock shares issued | shares	40,000,000	59,990,000	10,000
Par value for issued shares | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Value of common stock shares issued | $	$ 200,000	$ 59,990	$ 10
Number of shareholder | Shareholder	26	45